National Genomics Board

The National Genomics Board brings together senior decision makers across the sector, including key civil servants, delivery partners, patient advocates and representatives from research organisations and industry.

The purpose of the Board is to oversee the implementation of the Chief Medical Officer’s 2016 annual report, Generation Genome and the genomic elements of the Life Sciences Industrial Sector Deal.

Its goal is to make sure that the UK remains the world’s leading centre for genomic medicine and research, and to use this position to deliver quantifiable benefits for NHS patients and the life sciences sector.

Terms of Reference

The National Genomics Board will:

  • advise the UK government and be a mechanism for collaborative work to harness the benefits of genomics for health
  • agree a set of stretching ambitions for healthcare, life sciences and the development of a thriving genomics industry
  • consider how these working partnerships can contribute to the delivery of these ambitions by:

    • establishing and supporting the new NHS Genomic Medicine Service
    • creating and implementing a world leading research platform
    • ensuring that the UK has the capability and capacity to take full advantage of the research platform

It will make proposals on:

  • patient and public involvement
  • research activities, skills and training
  • genomics and life science industry
  • regulatory requirements, policy and guidance

The National Genomics Board will report to the new Life Sciences Council on the relevant aspects of the Life Sciences sector deal. The Life Sciences Council is chaired by the Secretaries of State for Health and Social Care and for Business Energy Industrial Strategy.

The National Genomics Board will report to the Life Sciences Council via the Life Sciences Industrial Strategy Implementation Board.


  • Baroness Blackwood, Parliamentary Under Secretary of State for Health (Lords) – chair
  • Professor Sir John Bell, vice chair, Regius Professor of Medicine, University of Oxford
  • Professor Dame Sally Davies, Chief Medical Officer for England
  • Dr Patrick Vallance, Chief Scientific Adviser to UK Government
  • David Williams, Director General, Finance and Group Operations, DHSC
  • Katie Farrington, Director for Technology, Digital and Data, NHSX
  • Dr Louise Wood, Director of Science, Research and Evidence, DHSC
  • Kristen Mcleod, Director of the Office for Life Sciences, BEIS/DHSC
  • Jonathan Symonds, Chair, Genomics England
  • Professor Sir Mark Caulfield, interim CEO, Genomics England
  • Lord David Prior, Chair, NHS England
  • Professor Dame Sue Hill, NHS Chief Scientific Officer for England, NHS
  • Professor Sir Mark Walport, Chief Executive, UK Research and Innovation
  • Professor Sara Marshall, Head of Clinical and Physiological Sciences, Wellcome Trust
  • Professor Charles Swanton, Chief Clinician, Cancer Research UK
  • Professor Fiona Watt, Executive Chair, Medical Research Council
  • Professor Sir Alex Markham, Chair, OSCHR subgroup on Health Informatics
  • Dr Jayne Spink, Chief Executive, Genetic Alliance
  • Deborah Alsina, Chief Executive, Bowel Cancer UK
  • Dr Eliot Forster, independent industry representative
  • Dr Ruth March, Senior Vice-President, Head of Personalised Healthcare and Biomarkers, AstraZeneca
  • Dr Tony Wood, Senior Vice-President, Platform Technology & Sciences, GSK
  • Alistair Henderson, Chief Executive, Academy of Medical Royal Colleges
  • Professor David Crossman, Scottish Government Representative
  • Dr Rob Orford, Welsh Government Representative
  • Professor Ian Young, Northern Ireland Government Representation